BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23221565)

  • 21. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
    Sanders RW; Venturi M; Schiffner L; Kalyanaraman R; Katinger H; Lloyd KO; Kwong PD; Moore JP
    J Virol; 2002 Jul; 76(14):7293-305. PubMed ID: 12072528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    Trkola A; Purtscher M; Muster T; Ballaun C; Buchacher A; Sullivan N; Srinivasan K; Sodroski J; Moore JP; Katinger H
    J Virol; 1996 Feb; 70(2):1100-8. PubMed ID: 8551569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
    Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.
    Pashov A; MacLeod S; Saha R; Perry M; VanCott TC; Kieber-Emmons T
    Glycobiology; 2005 Oct; 15(10):994-1001. PubMed ID: 15917430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
    Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
    PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen.
    Liu CC; Zhai C; Zheng XJ; Ye XS
    ACS Chem Biol; 2016 Jun; 11(6):1702-9. PubMed ID: 27088577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.
    Platt EJ; Gomes MM; Kabat D
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7829-34. PubMed ID: 22547820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.
    Zhang H; Fu H; Luallen RJ; Liu B; Lee FH; Doms RW; Geng Y
    Vaccine; 2015 Sep; 33(39):5140-7. PubMed ID: 26277072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.
    Douagi I; Forsell MN; Sundling C; O'Dell S; Feng Y; Dosenovic P; Li Y; Seder R; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Feb; 84(4):1683-95. PubMed ID: 19955308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.
    Astronomo RD; Kaltgrad E; Udit AK; Wang SK; Doores KJ; Huang CY; Pantophlet R; Paulson JC; Wong CH; Finn MG; Burton DR
    Chem Biol; 2010 Apr; 17(4):357-70. PubMed ID: 20416507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
    Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
    Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
    Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
    Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.
    Forthal DN; Gach JS; Landucci G; Jez J; Strasser R; Kunert R; Steinkellner H
    J Immunol; 2010 Dec; 185(11):6876-82. PubMed ID: 21041724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.
    Duenas-Decamp MJ; Clapham PR
    J Virol; 2010 Sep; 84(18):9608-12. PubMed ID: 20610714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STD NMR study of the interactions between antibody 2G12 and synthetic oligomannosides that mimic selected branches of gp120 glycans.
    Enríquez-Navas PM; Chiodo F; Marradi M; Angulo J; Penadés S
    Chembiochem; 2012 Jun; 13(9):1357-65. PubMed ID: 22628288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.
    Chaillon A; Braibant M; Moreau T; Thenin S; Moreau A; Autran B; Barin F
    J Virol; 2011 Apr; 85(7):3642-8. PubMed ID: 21248038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.